on TRANSGENE (EPA:TNG)
Transgene presents its innovative oncolytic virus at SITC 2026
Transgene, a biotechnology company specializing in cancer immunotherapies, will unveil a poster on its research at SITC 2026. This conference will be held in Phoenix (Arizona, USA) from November 4 to 8, 2026.
The poster will highlight PoxSTG-EEV, an enveloped oncolytic virus designed for systemic delivery. The corresponding abstract, titled "PoxSTG-EEV: a Novel Enveloped Virion–Based Formulation of a Chimeric Oncolytic PoxVirus Adapted for Systemic Delivery," will be available on November 3, 2026.
Transgene is thus continuing its efforts in the development of innovative treatments based on viral vectors, strengthening its position in the biotechnology market.
R. E.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all TRANSGENE news